Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating GSK3915393 for idiopathic pulmonary fibrosis was terminated, indicating the study did not continue to completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• GSK3915393

Snippet

Sponsor: GlaxoSmithKline | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: TERMINATED